Page 39 - Viral Vector News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New approach could treat infertility caused by abnormal GnRH secretion Reports suggest that at least 25% of ovarian disorders are due to dysfunction of the brain mechanism in the hypothalamus that controls the gonadotropin-releasing hormone (GnRH), which is a molecule that governs the reproductive function in men and women by regulating the release of a range of reproductive hormones into the body, particularly gonadotropins, from the pituitary gland, which is located underneath the brain. In a healthy individual, GnRH and gonadotropins are released in pulses, while typically in individuals w...

Delayed second dose strategy with mRNA vaccines may reduce COVID-19 mortality, say researchers An interesting new preprint on the medRxiv* server shows that even if countries are forced to delay the second dose of the current vaccines administered against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to arrest the ongoing coronavirus disease 2019 (COVID-19) pandemic, the cumulative mortality would still fall significantly. The study aimed to provide an in-silico estimation of the health outcomes in the population, given either as originally scheduled or with a delay in th...

Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a master research agreement with the Center for Innovation in Advanced Development and Manufacturing (CIADM) at Texas A&M University Health Science Center (TAMHSC). The agreement covers joint research and development projects for plasmid, protein and viral vector products in compliance with FDA regulations.

The single dose vaccine was given the clear by the U.S. Food and Drug Administration for use by people 18 or older on Feb. 27.

Cédric Szpirer, Founder and Executive Director of Delphi Genetics, added, “The complementary activities and adjacent technologies will provide our customers, our employees, and ultimately patients around the world with a solid foundation for new therapeutic solutions in the cell and gene therapy domain.” Upon completion, all of Delphi’s highly skilled team, including R&D and genetic engineering scientists and technicians, regulatory specialists, and other associated roles will transfer to Catalent’s Cell and Gene Therapy business. This acquisition fast-tracks Catalent’s U.S. expans...